COVID-19 Impact Analysis on Global Syndromic Multiplex Diagnostic market
The COVID19 pandemic has a significant impact on market growth. Healthcare system worldwide was under unprecedented strain by the serious impact of Covid-19. The increasing outbreak of various infectious and communicable diseases and viruses such as Covid-19, Flu, tuberculosis has led to demand for diagnostic device in the hospital. Hospitals experienced increased pressure to ensure the safety of patients and provide accurate result within time frame. Hence, the spread of Covid-19 has increased the demand for diagnostic market and services due to the growing cases of diseases in the hospital.
Rising advancement in the diagnostic technologies coupled with the rise in demand for the accurate diagnostic results have created demand for multiplex diagnostic market. Syndromic multiplex diagnostic test is affordable is providing growth of this market in developing regions where disposable income is rising. Syndromic multiplex is used for various infectious diseases including, Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV), Human Papillomavirus (HPV), Influenza, Chlamydia/Gonorrhea (CTGC), Tuberculosis, Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus (VRE). Rise in the prevalence of viral and bacterial infections provide lucrative market growth opportunity. Increasing in the demand by both patients and the healthcare provider for advanced diagnostic technologies which provide accurate and reliable results without consuming time is another factor fueling syndromic multiplex diagnostic. Moreover, syndromic multiplex diagnostic technologies help to diagnosis and detect the sing and symptoms of the diseases within a less time and it provide more accurate, realistic and comprehensive result.
Lack of awareness among people for syndromic multiplex diagnostic market is hindering the growth. The disability to detect asymptomatic cases restrain the rate of the market growth.
Rise in the prevalence of viral and bacterial infections coupled with the side effects of antibiotics consumed are providing sufficient and lucrative market growth opportunities.
Market Growth Challenge
Unwillingness to shift from traditional diagnostics techniques and measures by healthcare providers especially in the underdeveloped countries is created major challenge to the growth of the market.
Cumulative Growth Analysis
The report provides in-depth analysis of global syndromic multiplex diagnostic market, market size, and compound annual growth rate (CAGR) for the forecast period of 2022-2028, considering 2021 as the base year. With increasing demand for various syndromic multiplex diagnostic market in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2022-2028.
Market Segmental Overview
The global Syndromic Multiplex Diagnostic market comprises of different market segment like infectious disease, type of syndrome, end-user and geography.
Syndromic Multiplex Diagnostic market by Infectious Disease
The Infectious disease studied in the global syndromic multiplex diagnostic market are, Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV), Human Papillomavirus (HPV), Influenza, Chlamydia/Gonorrhea (CTGC), Tuberculosis, Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus (VRE). The Human immunodeficiency virus segment account largest share in the syndromic multiplex diagnostic market. HIV diagnostic is remarkable progress in identifying, staging, imitating and monitoring infected individual on life saving antiretroviral therapy. Accurate diagnosis of HIV infection is key and represent the entry point of infected patients into the treatment. Early HIV detection and treatment is important because it reduce patient mortality and prevent future HIV transmissions.
Syndromic Multiplex Diagnostic market by Type of Syndrome
The type of syndrome studied in the global syndromic multiplex diagnostic market are, Bloodstream, Respiratory, Gastrointestinal, Central Nervous System, others. Respirator segment account largest share in the syndromic multiplex diagnostic market. Rising higher demand due to the rapid spread of infections along with the launch of new with USFDA approval that contribute major growth in the global syndromic multiplex diagnostic market. Respiratory tract infection is the most frequent cause of acute illness in developed countries. The majority of respiratory infections are caused by viruses, the most common viruses are rhinovirus, coronaviruses, influenza virus and other. The COVID-19 crises put a burden on healthcare providers to quickly and accurately distinguish between respiratory pathogen that often produce similar symptoms in patient. The demand for syndromic multiplex diagnostic market was high during the COVID-19.
Syndromic Multiplex Diagnostic market by end-User
The end-user studied in the global syndromic multiplex diagnostic market are, Hospitals, Diagnostics Laboratories, Research Institutes and others. The hospital segment account largest share in the syndromic multiplex diagnostic market. Owing to the availability of all resources at a single facility. The reduction of the overall stay of patients for treatment in hospitals with the reduced procedural time along with minimal and errors in the treatment is boosting the syndromic multiplex diagnostic market growth. Increasing in the demand by both patients and the healthcare provider for advanced diagnostic technologies which provide accurate and reliable results without consuming time is another factor fueling syndromic multiplex diagnostic.
Syndromic Multiplex Diagnostic market by Geography
The global syndromic multiplex diagnostic market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North -America is likely to witness rising demand for nitrogen gas separation membrane market. Rising adoption of advanced technologies and the availability of improved healthcare infrastructure and also rising in research and development laboratories resultant. The syndromic multiplex diagnostic demand is growing for treatments with widespread infections, rise in government supports to spread the healthcare awareness among people about various infections in the region. The prevalence of high adoption rate for advanced diagnostic technologies with sophisticated healthcare infrastructure in this region growing demand for syndromic multiplex diagnostic market in North-America. On other hand Asia-Pacific region is growing region owing to rise in awareness and demand for syndromic multiplex diagnostic with rising disposable income.
Competitive Landscape Analysis
The competitive landscape analysis of syndromic multiplex diagnostic market is certainly based range of market players operating in the market with increasing demand for quick Access to the Treatment and Reduction of the Adverse Reactions of Antibiotics. Besides, number of market players offered wide range of type of syndrome for various end-users in various geographic locations. The market has major competitive analysis based on new product launches as well as other developments.
The key players studied in market are, Qiagen BIOMERIEUX SA (BioFire Diagnostics), Luminex Corporation, Applied BioCode, Akonni Biosystems, Mesa Biotech, Abbott Laboratories, Diagenode Diagnostics, Accelerate Diagnostic, Hologic, Inc., GenMark Diagnostics, Inc, Inflammatix, Inc., Janssen Pharmaceuticals, Inc. Bio-Rad Laboratories, Inc., Bosch Healthcare Solutions GmbH, Bio-Rad Laboratories, Inc., Bosch Healthcare Solutions GmbH, Cepheid. and among others.
June 2021: Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, was acquired by Hologic, Inc. Mobidiag develops near-patient molecular diagnostic instruments and tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections.
October 2021: The Novodiag system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance, has been launched in Europe by Hologic. The Novodiag system combines real-time PCR with microarray technology.
June 2021: Bio-Rad Laboratories, inc. announced a collaboration with seegene, inc., a global leader in multiplex molecular diagnostics, to develop and commercialize infectious disease molecular diagnostic products.
March 2021: Biomerieux had announced that Biofire Diagnostics which is a subsidiary specialized in molecular syndromic infectious diseases had received U.S food and drug administration de Novo authorization for the BIOFIRE RP2.1 panel.
November 2021: Qiagen NV has launched and CE-marking of thw QIAstart-Dx respiratory 4 plex flu A-B/RSV/SARS-Cov-2 test for the QIAstart-dx system o quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.